Efficacy of adjuvant chemotherapy for elderly patients with colon cancer
0502 economics and business
05 social sciences
DOI:
10.1093/annonc/mdy151.231
Publication Date:
2018-06-20T06:14:05Z
AUTHORS (15)
ABSTRACT
Introduction: The benefit of adjuvant chemotherapy (fluoracil or capecitabine with without oxaliplatin) has been well established in the setting for node-positive colon cancer (stage III). extent to which older adults from was not different trials (MOSAIC, NSABP C-07, N016968) given that there no participation patients than 75 years old. However, latest published systematic reviews are contradictory results on efficacy this population. Methods: We retrospectively included stages II and III underwent surgical treatment between 2009 2014 at University Hospital Ramón y Cajal (Madrid). calculated DFS OS 48 months we performed a univariate multivariate Cox model analysis estimate age groups (cut-off point 70 years) stage diagnosis. further adjusted by including following confounding factors: ECOG-PS, grade, number resected nodes, CEA before surgery, side location, presence obstruction/perforation. A covariate considered factor if difference unadjusted coefficient varied> 10%. Stata 13.1 used analyse data. Results: 551 were identified (166 <70 old 385 ≥ old). 281 (51%) 220 270 (49%) 165 In addition, had ECOG-PS: 0 but 331 ECOG-PS greater (43%, 1). 248 received 303 did not. median follow-up entire cohort 49 months. reached moment analysis. both 78.5%. Globally, improve (HR 0, 72, p 43) significantly better 36, 0,005). By stage, (HR: 67, p: 0.2) nor 0.4, 0.085). III, showed trend de 23, 58) clearly 0,071, 0,002). Nevertheless, global population shows 0,657 0,031) 0,257 (IC: 0,149 – 0,445) 0,002) probably affected factors (ECOG-PS, obstruction/perforation nodes). Conclusion: multivariable cancer, 77% reduction risk recurrence 29% death. these benefits found either PFS OS. More prospective studies group needed confirm findings.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (2)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....